Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer.
Marta Herreros-Villanueva, Saray Duran-Sanchon, Ana Carmen Martín...
https://pubmed.ncbi.nlm.nih.gov/30702491/Actively Recruiting
Led by ADVANCED MARKER DISCOVERY S.L. · Updated on 2025-10-01
250
Participants Needed
5
Research Sites
N/A
Total Duration
This research aims to evaluate the false positive rate of a blood test that uses molecular biomarkers and risk factors identified by artificial intelligence tools. The study includes 250 patients diagnosed with various cancers and gastrointestinal diseases, excluding colorectal cancer. The main goal is to determine if the blood test has a low false positive rate in this group. Participants will provide a blood sample for molecular analysis as part of their regular medical care. The study includes patients with different cancer types such as breast cancer, bladder cancer, leukemia, lung cancer, and inflammatory bowel diseases. This is an observational study without treatment interventions. During the study, participants will donate a blood sample and provide consent to access their clinical risk factors. Researchers will monitor the accuracy of the blood test over 36 months by measuring the rate of false positives. The total participation involves routine care procedures and sample collection for molecular testing, with no additional invasive procedures.
CONDITIONS
Observational Cross-reactivity Study for Colorectal Cancer Diagnosis
M
Marta Jimenez
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
ADVANCED MARKER DISCOVERY S.L.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants provide a blood sample for molecular analysis of biomarkers related to colorectal cancer diagnosis.
1 visit (in-person)
Duration - Up to 36 months
Participants are monitored to evaluate the specificity of the blood test over time.
Follow-up visits as needed
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Marta Herreros-Villanueva, Saray Duran-Sanchon, Ana Carmen Martín...
https://pubmed.ncbi.nlm.nih.gov/30702491/Hyuna Sung, Jacques Ferlay, Rebecca L Siegel...
https://pubmed.ncbi.nlm.nih.gov/33538338/Rebecca L Siegel, Nikita Sandeep Wagle, Andrea Cercek...
https://pubmed.ncbi.nlm.nih.gov/36856579/ADVANCED MARKER DISCOVERY S.L.
Lead Sponsor